Lipocalyx GmbH, a Wolfen, Germany-based newly founded company focused on development of transfection reagents for siRNA based on innovative polymers, has closed its seed funding round.
Backers include High-Tech Gründerfonds and GoodVent, which both will have a seat on the company’s board.
Lipocalyx intends to use the funds to start its development activities in the field of siRNA delivery.
Led by founder and managing director Dr. Steffen Panzner, the company develops transfection reagents for siRNA based on innovative polymers. The focus of the application is on neuronal or immune cells, which, until now, have been difficult to transfect. Initial test results are expected in Spring 2012.